Literature DB >> 26429312

Association of a coding polymorphism in Fc gamma receptor 2A and graft survival in re-transplant candidates.

Marie-Luise Arnold1, Barbara G Fuernrohr2, Katrin M Weiß2, Ulrike Harre3, Michael S Wiesener4, Bernd M Spriewald5.   

Abstract

The family of Fc gamma receptors (FcγRs) is involved in mediating immunological effector functions. FcγRs are differentially expressed on immune cells and can act either activating or inhibitory, with FcγR2A belonging to the first group. The polymorphism H131R (rs1801274) in FCGR2A has been associated with acute rejection and can shift the overall balance between activating and inhibitory FcγRs. Anti-HLA allo-antibodies in transplant recipients have been identified as risk factor for organ survival after transplantation. In this study we genotyped FCGR2A H131R in 200 patients who had undergone kidney transplantation and experienced loss of graft function. FCGR2A polymorphism was related to graft survival and anti-HLA antibodies. Graft survival was calculated as the time interval between transplantation and return to chronic dialysis after transplantation. The gene frequency of FCGR2A R/R131 was found significantly more often in patients with earlier (⩽60months) compared to patients with later (>60months) graft failure. Overall patients homozygous for R/R131 had a significantly shorter graft survival, compared to H/H131 or H/R131 which is even more pronounced, when anti-HLA antibodies were present. These data suggest, that FCGR2A polymorphisms constitute a risk factor for graft loss following kidney transplantation and that this effect is related to anti-HLA antibodies.
Copyright © 2015 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anti-HLA antibodies; Fc gamma receptor 2A; Graft survival; Human leukocyte antigen; Renal transplantation

Mesh:

Substances:

Year:  2015        PMID: 26429312     DOI: 10.1016/j.humimm.2015.09.034

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  6 in total

1.  Correlation of Fc Receptor Polymorphisms with Pneumococcal Antibodies in Vaccinated Kidney Transplant Recipients.

Authors:  Marie-Luise Arnold; Falko M Heinemann; Simon Oesterreich; Benjamin Wilde; Anja Gäckler; David Goldblatt; Bernd M Spriewald; Peter A Horn; Oliver Witzke; Monika Lindemann
Journal:  Vaccines (Basel)       Date:  2022-05-05

Review 2.  Fcγ Receptors in Solid Organ Transplantation.

Authors:  Tomas Castro-Dopico; Menna R Clatworthy
Journal:  Curr Transplant Rep       Date:  2016-10-03

3.  FCGR3A and FCGR2A Genotypes Differentially Impact Allograft Rejection and Patients' Survival After Lung Transplant.

Authors:  Pascale Paul; Pascal Pedini; Luc Lyonnet; Julie Di Cristofaro; Anderson Loundou; Mathieu Pelardy; Agnes Basire; Françoise Dignat-George; Jacques Chiaroni; Pascal Thomas; Martine Reynaud-Gaubert; Christophe Picard
Journal:  Front Immunol       Date:  2019-06-12       Impact factor: 7.561

Review 4.  Sensitization in transplantation: Assessment of risk (STAR) 2019 Working Group Meeting Report.

Authors:  Anat R Tambur; Patricia Campbell; Anita S Chong; Sandy Feng; Mandy L Ford; Howard Gebel; Ronald G Gill; Garnett Kelsoe; Vasilis Kosmoliaptsis; Roslyn B Mannon; Michael Mengel; Elaine F Reed; Nicole M Valenzuela; Chris Wiebe; I Esme Dijke; Harold C Sullivan; Peter Nickerson
Journal:  Am J Transplant       Date:  2020-05-27       Impact factor: 8.086

5.  Functional Fc Gamma Receptor Gene Polymorphisms and Long-Term Kidney Allograft Survival.

Authors:  Markus Wahrmann; Bernd Döhler; Marie-Luise Arnold; Sabine Scherer; Katharina A Mayer; Susanne Haindl; Helmuth Haslacher; Georg A Böhmig; Caner Süsal
Journal:  Front Immunol       Date:  2021-08-23       Impact factor: 7.561

Review 6.  The Role of Fc Gamma Receptors in Antibody-Mediated Rejection of Kidney Transplants.

Authors:  Boris Delpire; Elisabet Van Loon; Maarten Naesens
Journal:  Transpl Int       Date:  2022-07-20       Impact factor: 3.842

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.